Cypress Seeks FDA Approval for Fibromyalgia Trials

San Diego Business Journal, Dec 17, 2001

San Diego-based Cypress Bioscience, Inc. said last month it filed for Food and Drug Administration approval to start a Phase II trial to evaluate its experimental drug for fibromyalgia syndrome.

Fibromyalgia syndrome is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body accompanied by severe fatigue and headache, Cypress said.

It affects an estimated 2 to 4 percent of the worldwide population and is the second most common diagnosis by rheumatologists in the United States after osteoarthritis, Cypress said.

There are no approved treatments for the condition today, the company said Dec. 6.